| Předmět: |
|
| Zdroj: |
Immunotherapy Weekly; 4/16/2024, p1212-1212, 1p |
| Abstrakt: |
A recent study conducted at St. Jude Children's Research Hospital explored the genomic determinants of response and resistance to inotuzumab ozogamicin (InO) in patients with B-cell acute lymphoblastic leukemia (ALL). The researchers analyzed pre- and post-InO patient samples and found acquired CD22 mutations in relapsed tumor samples. These mutations, along with other genetic alterations, influenced the efficacy of InO and contributed to resistance. The study highlights the importance of understanding the mechanisms of escape from CD22-targeted therapy and the need to eradicate residual disease before hematopoietic stem cell transplantation (HSCT). [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
